WHY THIS MATTERS
- 17% of all drug withdrawals from market are due to cardiac adverse events - cardiotoxicity is the #2 cause
- Traditional hERG-only screening misses 40% of drugs that cause fatal arrhythmias in humans
- CiPA-validated iPSC-cardiomyocyte models predict human risk with 85-90% accuracy
- FDA now accepts CiPA data for cardiac safety assessment, reducing reliance on animal QT studies
- Heart-on-chip systems enable study of chronic cardiotoxicity impossible in standard cell cultures
EXECUTIVE SUMMARY
Cardiac models represent the most clinically advanced application of NAM technology. The FDA's Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative has created a validated framework for using human iPSC-derived cardiomyocytes to assess drug-induced arrhythmia risk. Combined with heart-on-chip microfluidic systems, these technologies now predict human cardiotoxicity with 85-90% accuracy compared to approximately 50% for animal models.
Cardiotoxicity is the second leading cause of drug withdrawal after hepatotoxicity, accounting for 17% of all market withdrawals. The pharmaceutical industry loses over $800 million annually from late-stage cardiac safety failures. Human cardiac models are addressing this challenge by providing species-specific, mechanistically relevant data that translates directly to clinical outcomes.
IN THIS GUIDE
What Are Cardiac Models?
Cardiac models are laboratory systems that replicate the structure and function of the human heart for drug testing and disease research. Unlike traditional 2D cell cultures, modern cardiac models recreate the complex 3D architecture, electrical signaling, and mechanical beating of heart tissue.
The heart presents unique challenges for in vitro modeling because it is an electromechanical organ - it must both conduct electrical signals and contract rhythmically. Drug-induced cardiac toxicity can affect ion channels (causing arrhythmias), contractile proteins (causing heart failure), or structural integrity (causing cardiomyopathy).
Types of Cardiac Models
- iPSC-Derived Cardiomyocytes (iPSC-CMs): Human heart cells differentiated from induced pluripotent stem cells. The most widely used and CiPA-validated platform for cardiac safety screening.
- Heart-on-Chip: Microfluidic devices containing beating cardiomyocytes with real-time monitoring of contractility and electrophysiology.
- Cardiac Organoids: Self-organizing 3D structures that develop chamber-like features and mimic heart development.
- Engineered Heart Tissue (EHT): Cells seeded in scaffolds that form functional tissue strips with measurable force generation.
- Cardiac Spheroids: Simpler 3D aggregates used for high-throughput screening.
The CiPA Framework: A New Paradigm for Cardiac Safety
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative represents a fundamental shift in how cardiac safety is assessed during drug development. Launched by the FDA in collaboration with international regulators and industry, CiPA moves beyond simple hERG channel blocking to a more mechanistic, human-relevant approach.
The Problem with Traditional Testing
For decades, cardiac safety testing relied primarily on the hERG assay - measuring a drug's ability to block the hERG potassium channel that controls heart rhythm. However, this approach has critical limitations:
- hERG blocking alone doesn't predict clinical arrhythmia risk - many safe drugs block hERG
- Drugs can cause arrhythmias through non-hERG mechanisms that aren't detected
- Animal QT studies often don't translate to human cardiac effects
- Many potentially safe drugs are killed in development due to hERG "false positives"
The CiPA Solution: Three Pillars
CiPA integrates three complementary approaches:
- Ion Channel Panel: Testing against 7 cardiac ion channels (not just hERG) including Nav1.5, Cav1.2, Kv4.3, and others that contribute to cardiac action potential
- In Silico Modeling: Computer models that integrate ion channel data to predict action potential changes and proarrhythmic risk
- Human iPSC-Cardiomyocyte Confirmation: Functional validation in human heart cells that express all relevant ion channels in physiological context
CiPA Validation Results
The CiPA validation study tested 28 reference compounds with known clinical cardiac safety profiles. Results demonstrated that the integrated CiPA approach correctly classified drugs into torsade risk categories with 85-90% accuracy, significantly outperforming hERG-only testing.
iPSC-Derived Cardiomyocytes: The Gold Standard
Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have become the cornerstone of cardiac safety assessment. These cells are generated by reprogramming adult human cells (typically skin or blood cells) into stem cells, then differentiating them into beating heart cells.
Key Advantages of iPSC-CMs
- Human-Specific: Express human ion channels, receptors, and metabolic enzymes
- Unlimited Supply: Can be produced in large quantities from characterized cell lines
- Genetic Diversity: Can be derived from patients with cardiac diseases or specific genotypes
- Functional Readouts: Beat spontaneously, allowing measurement of contractility and electrophysiology
- CiPA Validated: Recognized by FDA for cardiac safety applications
Measuring Cardiac Function in iPSC-CMs
Multiple parameters can be measured to assess drug effects:
- Action Potential Duration (APD): Prolongation indicates QT risk
- Beat Rate: Changes in spontaneous beating frequency
- Contractility: Force and velocity of contraction
- Arrhythmia Events: Early afterdepolarizations (EADs), triggered activity
- Calcium Transients: Intracellular calcium handling
- Cell Viability: Structural cardiotoxicity
Commercial iPSC-CM Suppliers
- FUJIFILM Cellular Dynamics (iCell): Pioneer in commercial iPSC-CMs, CiPA validated
- Ncardia: Pluricyte cardiomyocytes with standardized protocols
- Takeda (Axiogenesis): Cor.4U cardiomyocytes used in CiPA studies
- Stemcell Technologies: Research-grade iPSC-CMs and differentiation kits
- Elixirgen Scientific: Quick-diff cardiomyocytes for rapid production
Heart-on-Chip: Advanced Microfluidic Platforms
Heart-on-chip systems combine iPSC-cardiomyocytes with microfluidic technology to create more physiologically relevant cardiac models. These platforms add mechanical stimulation, continuous perfusion, and real-time monitoring capabilities that are impossible in standard cell cultures.
Key Features of Heart-on-Chip Systems
- Continuous Flow: Mimics blood circulation, enabling chronic drug exposure studies
- Mechanical Stretching: Simulates the cardiac cycle's mechanical forces
- Multi-Electrode Arrays (MEA): Real-time electrophysiology monitoring
- Integrated Sensors: Oxygen, pH, and metabolite monitoring
- 3D Architecture: Cells organize into tissue-like structures
Leading Heart-on-Chip Platforms
- Emulate Heart-Chip: Part of the Body-on-Chip platform, enables multi-organ studies
- BioPace: Functional cardiac tissue strips with force measurement
- InSphero: 3D cardiac microtissues for high-throughput screening
- TARA Biosystems: Biowire platform for mature cardiac tissue
- Novoheart: Human ventricular cardiac organoid chamber (hvCOC)
Advantages Over Standard Cell Culture
Heart-on-chip systems enable studies that are impossible in conventional formats:
- Chronic Toxicity: Weeks-long drug exposure to detect cumulative damage
- Metabolite Effects: Liver-heart chip combinations to study metabolite cardiotoxicity
- Disease Modeling: Recapitulating heart failure, arrhythmia, and cardiomyopathy
- Drug-Drug Interactions: Testing combination therapies
Cardiac Organoids: Self-Organizing Heart Models
Cardiac organoids take a different approach than engineered tissues - they leverage the self-organizing capacity of stem cells to spontaneously form heart-like structures with chambers, defined cell types, and developmental patterning.
Types of Cardiac Organoids
- Cardioids: Heart organoids that develop chamber-like structures with atrial and ventricular regions
- Heart Field Organoids: Model early cardiac development and congenital defects
- Cardiac Spheroids: Simpler 3D aggregates for screening applications
Research Applications
Cardiac organoids are particularly valuable for:
- Developmental Biology: Understanding heart formation and congenital defects
- Regenerative Medicine: Developing cell therapy approaches
- Disease Modeling: Patient-specific models of cardiomyopathy
- Structural Cardiotoxicity: Long-term drug effects on heart structure
Drug Safety Applications
QT Prolongation and Arrhythmia Risk
The most critical application of cardiac models is assessing proarrhythmic risk. QT prolongation on the ECG indicates delayed cardiac repolarization, which can trigger fatal ventricular arrhythmias (Torsades de Pointes). iPSC-CMs can detect:
- Action potential duration changes
- Early afterdepolarizations (EADs)
- Triggered arrhythmia events
- Beat rate irregularities
Structural Cardiotoxicity
Some drugs, particularly cancer therapeutics like anthracyclines and tyrosine kinase inhibitors, cause cumulative damage to heart muscle. Cardiac models can assess:
- Anthracycline Toxicity: Doxorubicin-induced cardiomyopathy
- Tyrosine Kinase Inhibitor Effects: Imatinib, sunitinib cardiotoxicity
- HER2 Inhibitor Monitoring: Trastuzumab cardiac dysfunction
- Checkpoint Inhibitor Myocarditis: Immune-mediated cardiac inflammation
Contractility and Inotropy
Beyond arrhythmia, drugs can affect the heart's ability to contract effectively. Cardiac models measure inotropic (contractility) and chronotropic (heart rate) effects that predict clinical hemodynamic consequences.
Cardiac Model Technology Comparison
| Feature | iPSC-CMs (2D) | Heart-on-Chip | Cardiac Organoids | Animal Models |
|---|---|---|---|---|
| Human Relevance | High | Moderate | ||
| CiPA Validated | Yes | Emerging | No | |
| Throughput | High (384-well) | Low-Medium | Medium | Very Low |
| Cost per Test | $50-200 | $500-2,000 | $200-500 | $5,000-50,000 |
| Chronic Studies | Limited (days) | Weeks-Months | Weeks | Months |
| Maturity Level | Fetal-like | More Mature | Variable | Adult |
| Arrhythmia Prediction | 85-90% | Emerging | 50-60% |
Leading Companies in Cardiac Modeling
iPSC-Cardiomyocyte Providers
- FUJIFILM Cellular Dynamics: Industry leader with iCell Cardiomyocytes, the most widely used CiPA-validated platform. Supplies 90%+ of major pharma companies.
- Ncardia: European leader with Pluricyte cardiomyocytes and drug discovery services.
- Stemcell Technologies: Research-grade iPSC-CMs and comprehensive reagent portfolio.
Heart-on-Chip Companies
- Emulate: Heart-Chip platform integrated with multi-organ Body-on-Chip system.
- TARA Biosystems: Biowire platform for functional cardiac tissue with force measurement.
- Novoheart: Human ventricular cardiac organoid chamber for contractility studies.
Assay Platform Providers
- Molecular Devices: FLIPR and IonWorks platforms for high-throughput cardiac assays.
- Axion BioSystems: Maestro MEA system for cardiac electrophysiology.
- Nanion Technologies: Automated patch clamp for ion channel screening.
Regulatory Status and Acceptance
Cardiac models have achieved significant regulatory acceptance, making them the most mature NAM application in drug development.
FDA Position
- CiPA Endorsement: FDA supports the CiPA framework as a more mechanistic approach to cardiac safety assessment
- ICH S7B/E14 Q&A: Updated guidance incorporates CiPA concepts, allowing sponsors to use iPSC-CM data to support clinical QT study design
- IND Submissions: Multiple sponsors have included CiPA data in IND applications
International Harmonization
- EMA: Accepts CiPA data as part of integrated risk assessment
- PMDA (Japan): Active participant in CiPA development and validation
- Health Canada: Follows ICH guidelines incorporating CiPA concepts
Industry Adoption
Virtually all major pharmaceutical companies have incorporated iPSC-CM testing into their cardiac safety assessment workflows. The IQ Consortium's Cardiac Safety Working Group has published best practices for implementation.
Ion Channel Testing in Cardiac Safety
Understanding the role of different cardiac ion channels is essential for predicting arrhythmia risk. CiPA evaluates multiple channels beyond hERG to provide a complete picture of cardiac electrophysiology effects.
Key Insight: Multi-channel blocking drugs may have balanced effects that don't cause arrhythmia despite hERG block. For example, ranolazine blocks hERG but also inhibits late INa, resulting in no net proarrhythmic effect. CiPA captures these nuances that single-channel testing misses.
Cardiac Measurement Technologies
Multiple platforms enable quantitative assessment of iPSC-cardiomyocyte function for drug safety evaluation.
Extracellular field potential recording from cell monolayers. Measures FPD (QT surrogate), conduction velocity, and arrhythmia events. Maestro (Axion), ACEA (Agilent) platforms.
Fluorescent indicators for action potential and calcium transient imaging. Enables spatially-resolved measurements and wave propagation analysis. CellOPTIQ, Kinetic Image Cytometry.
Label-free measurement of cardiomyocyte beating. Impedance systems (xCELLigence) detect contractile motion. Video-based motion analysis provides beat amplitude, velocity, irregularity.
Direct force measurement from 3D cardiac tissue strips anchored between posts. Quantifies contractile force, kinetics, and drug-induced changes. Biowire, EHT platforms.
Types of Drug-Induced Cardiotoxicity
Different drug classes cause distinct forms of cardiac injury that require specific testing approaches.
Functional Cardiotoxicity (Arrhythmia Risk)
Mechanism: Ion channel blockade causing action potential prolongation and proarrhythmic effects.
Examples: Terfenadine, cisapride, droperidol, arsenic trioxide
Detection: CiPA testing (ion channels + in silico + iPSC-CM), MEA, QT prolongation assays
Timeline: Acute - occurs within hours of drug exposure
Structural Cardiotoxicity (Cardiomyopathy)
Mechanism: Direct cardiomyocyte injury, mitochondrial toxicity, oxidative stress leading to cell death and fibrosis.
Examples: Anthracyclines (doxorubicin), tyrosine kinase inhibitors (sunitinib, sorafenib)
Detection: Heart-on-chip chronic exposure, viability assays, biomarkers (troponin, BNP)
Timeline: Chronic - develops over weeks to months of exposure
Myocarditis (Immune-Mediated)
Mechanism: Immune cell infiltration and inflammation of heart muscle, often involving T-cells.
Examples: Immune checkpoint inhibitors (nivolumab, pembrolizumab), clozapine
Detection: Emerging - immune cell co-culture systems, multi-organ chips with immune component
Timeline: Variable - can occur early or late in treatment
Contractility Effects (Inotropy)
Mechanism: Changes in cardiac contractile force (positive or negative inotropy) affecting cardiac output.
Examples: Beta-blockers (negative), digoxin (positive), calcium channel blockers (negative)
Detection: Contractility assays, engineered heart tissue force measurement, impedance
Timeline: Acute - occurs with drug exposure